| Rx0000234 |
Optinose US, Inc. |
03/31/2023 |
71143037501 |
XHANCE (fluticasone propionate) (Nasal) 93 MCG/ACT Exhaler Suspension, 1 Exhaler of 16 ML |
Brand |
FDA |
01/01/2023 |
28.43 |
596.97 |
02/23/2036 |
Single Source Drug |
395476 |
None |
Optinose took a 5% price increase on 1/1/2023 as a result of increases in PBM rebates, increases in distribution costs and inflationary factors. |
None |
N/A |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000375 |
Organon |
12/31/2023 |
78206015001 |
Pregnyl for Injection 10,000 units/1 vial in package |
Brand |
FDA |
10/02/2023 |
53.74 |
170.00 |
None |
Single Source Drug |
None |
1 |
This new price represents a market adjustment to align PREGNYL’s WAC pricing more closely with that of the other therapies. PREGNYL’S pricing has remained flat relative to the market for years, where other products in this therapeutic space have taken consistent price increases. PREGNYL’s previous WAC of $116.26 was approximately 63% lower than Novarel and the Fresenius generic, and 47% lower than Ovidrel, and the current price of $170 still represents a 46% discount to the generic. |
None |
Not applicable |
None |
06/02/2023 |
Merck Sharp & Dohme |
None |
1 |
Organon is the resulting organization from the divesture of Merck's women's health division, biosimilars, and select legacy products. For clarity, this product being sold under the Organon label are not new to market products as they existed previously under Merck but are being sold now under the Organon label. |
116.26 |
106.56 |
1993 |
25.00 |
None |
Pregnyl no longer under patent, no date to report. |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148004580 |
Abilify Maintena 300mg Dual Chamber Syringe |
Brand |
FDA |
01/15/2023 |
124.47 |
2039.42 |
09/24/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148001871 |
Abilify Maintena 300mg Kit |
Brand |
FDA |
01/15/2023 |
124.47 |
2039.42 |
09/24/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148007280 |
Abilify Maintena 400mg Dual Chamber Syringe |
Brand |
FDA |
01/15/2023 |
165.96 |
2719.23 |
09/24/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148001971 |
Abilify Maintena 400mg Kit |
Brand |
FDA |
01/15/2023 |
165.96 |
2719.23 |
09/24/2033 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148008213 |
Jynarque 15mg tablets, 30 count bottle |
Brand |
FDA |
01/15/2023 |
598.44 |
9805.14 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148007928 |
Jynarque 15mg/15mg 4x weekly blister cards |
Brand |
FDA |
01/15/2023 |
1117.08 |
18302.92 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148008313 |
Jynarque 30mg tablets, 30 count bottle |
Brand |
FDA |
01/15/2023 |
598.44 |
9805.14 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148008028 |
Jynarque 30mg/15mg 4x weekly blister cards |
Brand |
FDA |
01/15/2023 |
1117.08 |
18302.92 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148008728 |
Jynarque 45mg/15mg 4x weekly blister cards |
Brand |
FDA |
01/15/2023 |
1117.08 |
18302.92 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148008828 |
Jynarque 60mg/30mg 4x weekly blister cards |
Brand |
FDA |
01/15/2023 |
1117.08 |
18302.92 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148008928 |
Jynarque 90mg/30mg 4x weekly blister cards |
Brand |
FDA |
01/15/2023 |
1117.08 |
18302.92 |
04/07/2030 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148003513 |
Rexulti 0.25mg tablets, 30 count bottle |
Brand |
FDA |
01/15/2023 |
86.61 |
1419.04 |
10/12/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148003613 |
Rexulti 0.5mg tablets, 30 count bottle |
Brand |
FDA |
01/15/2023 |
86.61 |
1419.04 |
10/12/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148003713 |
Rexulti 1mg tablets, 30 count bottle |
Brand |
FDA |
01/15/2023 |
86.61 |
1419.04 |
10/12/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148003813 |
Rexulti 2mg tablets, 30 count bottle |
Brand |
FDA |
01/15/2023 |
86.61 |
1419.04 |
10/12/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148003913 |
Rexulti 3mg tablets, 30 count bottle |
Brand |
FDA |
01/15/2023 |
86.61 |
1419.04 |
10/12/2032 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000067 |
Otsuka America Pharmaceutical, Inc. |
03/31/2023 |
59148004013 |
Rexulti 4mg tablets, 30 count bottle |
Brand |
FDA |
01/15/2023 |
86.61 |
1419.04 |
12/23/2028 |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000495 |
Otter Pharmaceuticals LLC |
03/31/2023 |
10094021001 |
Sympazan (clobazam) oral film 10mg (1ct) |
Brand |
FDA |
01/01/2023 |
1.48 |
31.76 |
09/05/2039 |
Single Source Drug |
None |
1 |
Factors that contributed to the price increase:
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products. |
None |
No Change |
None |
10/26/2022 |
Acquestive Therapeutics, Inc. |
15000000 |
None |
None |
30.28 |
28.70 |
2018 |
26.00 |
None |
None |
| Rx0000495 |
Otter Pharmaceuticals LLC |
03/31/2023 |
10094021060 |
Sympazan (clobazam) oral film 10mg (60ct) |
Brand |
FDA |
01/01/2023 |
88.80 |
1905.60 |
09/05/2039 |
Single Source Drug |
None |
1 |
Factors that contributed to the price increase:
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products. |
None |
No Change |
None |
10/26/2022 |
Acquestive Therapeutics, Inc. |
15000000 |
None |
None |
1816.80 |
1722.00 |
2018 |
1560.00 |
None |
None |
| Rx0000495 |
Otter Pharmaceuticals LLC |
03/31/2023 |
10094022001 |
Sympazan (clobazam) oral film 20mg (1ct) |
Brand |
FDA |
01/01/2023 |
2.97 |
63.53 |
09/05/2039 |
Single Source Drug |
None |
1 |
Factors that contributed to the price increase:
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products. |
None |
No Change |
None |
10/26/2022 |
Acquestive Therapeutics, Inc. |
15000000 |
None |
None |
60.56 |
57.40 |
2018 |
52.00 |
None |
None |
| Rx0000495 |
Otter Pharmaceuticals LLC |
03/31/2023 |
10094022060 |
Sympazan (clobazam) oral film 20mg (60ct) |
Brand |
FDA |
01/01/2023 |
178.20 |
3811.80 |
09/05/2039 |
Single Source Drug |
None |
1 |
Factors that contributed to the price increase:
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products. |
None |
No Change |
None |
10/26/2022 |
Acquestive Therapeutics, Inc. |
15000000 |
None |
None |
3633.60 |
3444.00 |
2018 |
3120.00 |
None |
None |
| Rx0000495 |
Otter Pharmaceuticals LLC |
03/31/2023 |
10094020501 |
Sympazan (clobazam) oral film 5mg (1ct) |
Brand |
FDA |
01/01/2023 |
0.74 |
15.88 |
09/05/2039 |
Single Source Drug |
None |
1 |
Factors that contributed to the price increase:
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products. |
None |
No Change |
None |
10/26/2022 |
Acquestive Therapeutics, Inc. |
15000000 |
None |
None |
15.14 |
14.35 |
2018 |
13.00 |
None |
None |
| Rx0000495 |
Otter Pharmaceuticals LLC |
03/31/2023 |
10094020560 |
Sympazan (clobazam) oral film 5mg (60ct) |
Brand |
FDA |
01/01/2023 |
44.40 |
952.80 |
09/05/2039 |
Single Source Drug |
None |
1 |
Factors that contributed to the price increase:
Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and non-financial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action:
(1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products.
(2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products.
(3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products.
(4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products.
(5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products.
(6) Discounts and Rebates:? We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California’s Medicaid program, as well as wholesalers and pharmacies.? Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products.
(7) Inflation:? We consider the rate of annual inflation in our decisions around pricing our products. |
None |
No Change |
None |
10/26/2022 |
Acquestive Therapeutics, Inc. |
15000000 |
None |
None |
908.40 |
861.00 |
2018 |
780.00 |
None |
None |
| Rx0000192 |
OWP Pharmaceuticals, Inc. |
03/31/2023 |
69102063909 |
Lamotrigine USP Blue Starter Kit (35 25mg Tablets) |
Generic |
FDA |
02/01/2023 |
37.00 |
505.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000192 |
OWP Pharmaceuticals, Inc. |
03/31/2023 |
69102035911 |
Lamotrigine USP Green Starter Kit 98 Tablets (84 25mg, 14 100mg) |
Generic |
FDA |
02/01/2023 |
105.00 |
1414.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000192 |
OWP Pharmaceuticals, Inc. |
03/31/2023 |
69102013710 |
Lamotrigine USP Orange Starter Kit 49 Tablets (42 25mg, 7 100mg) |
Generic |
FDA |
02/01/2023 |
55.00 |
735.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000192 |
OWP Pharmaceuticals, Inc. |
03/31/2023 |
69102030601 |
Subvenite (lamotrigine USP) Blue Starter Kit (35 25mg Tablets) |
Generic |
FDA |
02/01/2023 |
37.00 |
505.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000192 |
OWP Pharmaceuticals, Inc. |
03/31/2023 |
69102031201 |
Subvenite (lamotrigine USP) Green Starter Kit 98 Tablets (84 25mg, 14 100mg) |
Generic |
FDA |
02/01/2023 |
105.00 |
1414.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
| Rx0000192 |
OWP Pharmaceuticals, Inc. |
03/31/2023 |
69102030001 |
Subvenite (lamotrigine USP) Orange Starter Kit, 49 Tablets (42 25mg, 7 100mg) |
Generic |
FDA |
02/01/2023 |
55.00 |
735.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |